“…Human cells that have lower levels of XRCC1 show significant sensitivity to DNA damaging agents like methyl methanesulfonate (MMS), poly(ADP-ribose) polymerase (PARP) inhibitors, and other DNA damage response and repair inhibitors [ 10 , 11 , 12 , 13 , 14 ]. Additionally, mutations in XRCC1 that reduce its ability to bind PARP1, POLβ, or interact with DNA have been shown to increase hypersensitivity to DNA damaging agents and increase genomic instability and chromosomal aberrations, promoting transformation [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. While several single nucleotide polymorphisms, R399Q and R280H, have been correlated with cancer risk, variations in the gene and protein expression levels of XRCC1 are more commonly noted, particularly in ovarian, breast, and gastric cancers [ 14 , 23 , 24 , 25 , 26 , 27 , 28 ].…”